Search Results - D. A. Napalkov
- Showing 1 - 20 results of 45
- Go to Next Page
-
1
Russian Trial ALGORITHM: Implementation of Combined Antihypertensive and Hypolipidemic Treatment for Clinical Efficacy Achievement in Routine Clinical Practice by D. A. Napalkov
Published 2020-01-01Aim. To study the clinical outcomes (achievement of target blood pressure [BP]) and tolerability of antihypertensive and hypolipidemic therapy with fixed combinations of indapamide/perindopril, amlodipine/perindopril, amlodipine/indapamide/perindopril and rosuvastatin in patients with hypertension a...
Get full text
Article -
2
THE SAFETY OF STATINS: WHAT A PHYSICIAN NEEDS TO KNOW by D. A. Napalkov
Published 2015-09-01Various aspects of the safety of statins in clinical practice are discussed: hepatotoxicity, myopathy and rhabdomyolysis, the impact on the diabetes and cognitive dysfunction onset, renal function impairment.
Get full text
Article -
3
STROKE PREVENTION IN INTERNIST PRACTICE by D. A. Napalkov, A. V. Zhilenko
Published 2016-01-01Stroke secondary prevention in internist practice is discussed in accordance with up to date guidelines. Modern pharmacotherapy includes antiaggregants or anticoagulants, statins, and antihypertensive drugs. The choice of drugs is mostly founded on the rules of evidence based medicine, which allow a...
Get full text
Article -
4
MANAGEMENT OF PATIENT WITH ARTERIAL FIBRILLATION: WHAT`S NEW? by D. A. Napalkov, A. A. Sokolova
Published 2016-12-01The literary review consists of two parts. The first takes into consideration the renewed European guidelines of 2016 for atrial fibrillation patients management. The accent is made on the renewed approaches for anticoagulation treatment regardless the gender, on new points in the risks of haemorrha...
Get full text
Article -
5
Elderly Patients with Atrial Fibrillation: Focus on Comorbidity and Safety of Anticoagulant Therapy by D. A. Napalkov, A. A. Sokolova
Published 2019-09-01The article discusses issues related to the prescription of anticoagulant therapy to elderly patients with atrial fibrillation (AF), especially those over 70 and 80 years of age. The relevance of the issue is primarily due to the prevalence of AF in this cohort of patients, and the second is due to...
Get full text
Article -
6
ACE inhibitor zofenopril effectiveness in arterial hypertension treatment by D. A. Napalkov, E. N. Golovenko
Published 2008-12-01.
Get full text
Article -
7
The rational approach to selection of anticoagulation for stroke prevention in patients with atrial fibrillation of non-valvular etiology by D. A. Napalkov, A. A. Sokolova
Published 2014-03-01The question of how to use most eff ectively and safely drugs from the group of oral anticoagulants for prevention of thromboembolic complications (TEC) in patients with atrial fi brillation (AF) non-valvular etiology is analyzed in this paper.
Get full text
Article -
8
Atrial Fibrillation: a Marker or Risk Factor for Stroke by B. A. Tatarsky, D. A. Napalkov
Published 2023-03-01Atrial fibrillation (AF) is strongly associated with stroke risk, but an association by itself does not necessarily imply causation. The question remains whether AF is a risk factor for stroke and whether treatment that reduces the severity of AF will also reduce the burden of stroke. On the other h...
Get full text
Article -
9
CARDIOPROTECTIVE AND NEPHROPROTECTIVE EFFECTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITOR RAMIPRIL by D. A. Napalkov, E. N. Golovenko
Published 2016-01-01There is grate interest to ACE inhibitors which have cardioprotective and neproprotective effects. Ramipril efficacy in ischemic heart disease prevention as well as ramipril positive effect on myocardium in adolescents is presented on the base of some trails. Ramipril ability to delay of diabetic an...
Get full text
Article -
10
Modern therapeutic potential of super-selective β<sup>1</sup>-adrenoblocker nebivolol by V. I. Makolkin, D. A. Napalkov
Published 1970-01-01Beta-adrenoblockers, included in any cardiovascular disease treatment standard, became a key part of clinical practice only in late XX century. Nebivolol is a highly selective beta-1 -adrenoiblocker, modulating endothelial NO release and subsequent physiological vasodilatation. Nebivolol has multipl...
Get full text
Article -
11
Optimal treatment strategies in comorbid patients with hypertension and dyslipidemia: the role of fixed-dose combinations by A. A. Sokolova, D. A. Napalkov
Published 2023-12-01The publication reflects the modern strategy and potential of various fixed-dose combinations in comorbid patients with hypertension and lipid metabolism disorders. Based on guidelines and key randomized studies, algorithms for prescribing combination drugs are proposed depending on the clinical cha...
Get full text
Article -
12
NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY by D. A. Napalkov, A. A. Sokolova
Published 2015-09-01Comparative analysis of oral anticoagulants (vitamin K antagonists and new drugs, including dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile of the new oral anticoagulants is significantly better than vitamin K antagonists profile, but requires con...
Get full text
Article -
13
Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease by I. S. Daabul, A. A. Sokolova, D. A. Napalkov
Published 2016-11-01Prevalence of atrial fibrillation (AF) in population is very high and continues to grow. According to the existing statistics its prevalence reaches about 2% so it is twice more, than it was considered in the last decade. Prevalence of AF among patients with chronic kidney disease (CKD) varies from...
Get full text
Article -
14
COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS by V. A. Sulimov, D. A. Napalkov, A. A. Sokolova
Published 2015-09-01Indirect comparisons of new oral anticoagulants are performed with focus on their safety. Apixaban, an oral inhibitor of Xa factor, nowadays can be considered as a drug with very good safety profile according to randomized trials results and performed indirect comparisons.
Get full text
Article -
15
Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review by B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov
Published 2019-11-01Direct oral anticoagulants (not vitamin K antagonists), unlike standard oral anticoagulants (e.g. warfarin), have a predictable manifestation of the anticoagulant effect and the possibility of using a fixed dose without the need for constant monitoring of the anticoagulant effect. The rapid onset an...
Get full text
Article -
16
ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOW TO COMBINE ANTIPLATELET AND ANTICOAGULANT THERAPY, DEPENDING ON THE CLINICAL SITUATION? by D. A. Napalkov, A. A. Sokolova, A. V. Rodionov
Published 2016-05-01Up-to-date European approaches to the management of patients with atrial fibrillation (AF) after acute coronary syndrome and/or percutaneous coronary interventions are considered. Features of antithrombotic therapy in the early (hospital) and the delayed periods (up to 1 year after acute ischemic ev...
Get full text
Article -
17
INTERRELATION BETWEEN PERSISTENT NECROSIS OF CARDIOMYOCYTES AND PROGNOSIS IN PATIENTS WITH CHRONIC HEART FAILURE by E. N. Golovenko, D. A. Napalkov, V. A. Sulimov
Published 2016-01-01Background. Chronic heart failure (CHF) progression is accompanied by remodeling of muscular, collagen and vascular elements of myocardium. This can lead to increase in serum concentrations of myocardial lesion markers (cardiac troponin I (TrI) and myoglobin) which seem to correlate with poor progno...
Get full text
Article -
18
Left Ventricular Thrombosis: Current Perspective and Use of Direct Oral Anticoagulants by A. D. Aga, A. A. Sokolova, D. A. Napalkov
Published 2023-01-01Left ventricular thrombus (LVT) is a serious risk factor for systemic embolism development. Despite the evident danger of this condition, current guidelines describe management of patients with this potentially fatal complication very briefly. LVT can complicate myocardial infarction where its incid...
Get full text
Article -
19
Metformin in metabolic syndrome treatment by V. I. Podzolkov, D. A. Napalkov, V. I. Makolkin
Published 2005-06-01Aim. To compare the influence of standard and complex (including metformin) antihypertensive therapy on 24- hour blood pressure monitoring (BPM), biochemical and hormonal parameters in patients with metabolic syndrome (MS). Material and Methods. The study included 54 patients with MS: 34 males and 2...
Get full text
Article -
20
The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality by B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov
Published 2020-05-01The purpose of this review is to analyze the results of randomized clinical trials, meta-analyses of cohort and observational studies in real clinical practice on the influence of dabigatran etexilate on the risk of myocardial infarction in patients with atrial fibrillation. A pivotal RE-LY study on...
Get full text
Article